Companies / IMU

IMUGENE LIMITED

ASX:IMUPharmaceuticals, Biotechnology & Life Sciences
489.7M shares on issueASX (delayed) · as of 28 July 2026$0.090price · delayed$44.1Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 126% in 24 months; 8 cash raises in 24 months

Cash runway0.0 quarters of funding
Share-count growth (24m)126.4%
Raise cadence (24m)8 cash raises
Options & rights overhang5.1% of sharesconsolidation-adjusted
In-the-money supply0.0% of sharesconsolidation-adjusted
Pending proposed issuesnone

IMUGENE LIMITED's ordinary share count grew 126.4% between July 2024 and July 2026, to 490M shares; this figure is adjusted for the approximately 1-for-34 share consolidation that occurred in May 2025. The company raised capital eight times in the 24-month window for total disclosed proceeds of A$135.0M, most recently a A$11.1M placement in July 2026. Options and rights could convert into 25M new shares, equal to 5.1% of the current share count, with the nearest expiry in August 2026 and 0% currently in the money; these option figures are consolidation-adjusted. At the March 2026 quarter IMUGENE reported A$529K cash, covering 0.0 quarters. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
5.1%
Max option dilution
0.0%
ITM option dilution
5
Raises · last 12 months
0.0 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-34 consolidation (29 May 2025). Latest count 489.7M per ASX (delayed) (28 July 2026).
276.4M354.7M433.0MJuly 25Jan 26July 26Cash raise · 2 July 2026Cash raise · 30 Apr 2026Cash raise · 9 Mar 2026Cash raise · 19 Dec 2025Cash raise · 12 Aug 2025

Cash runway

0.0 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$529k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
17 July 20263H · cancellationIMU : ORDINARY FULLY PAID489.7MAppendix 3H
13 July 20262A · quoted issueIMU : ORDINARY FULLY PAID489.7MAppendix 2A
9 July 20262A · quoted issueIMU : ORDINARY FULLY PAID416.0MAppendix 2A
7 July 20263H · cancellationIMU : ORDINARY FULLY PAID415.8MAppendix 3H
2 June 20263G · unquotedORDINARY FULLY PAID415.8MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

8 cash raises in the last 24 months · 5 in the last 12 months

$11.1M
Placement
2 July 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

consolidation-adjusted Figures rebased for the share consolidation in the last 24 months.

5.1%
Total overhang · of current shares
0.0%
In the money · at current price
24.7M
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
1 July 2026Kim DrapkinOther7k——3Y notice
30 June 2026Jakob DupontOther7k——3Y notice
30 June 2026Leslie ChongSell———3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026$PThird response in concurrent BTKi Cohort of azer-cel Trial
26 July 2026$PCEO Resignation
17 July 2026Notification of cessation of securities - IMU
16 July 2026Notice of Extraordinary General Meeting/Proxy Form
13 July 2026Cleansing Notice
13 July 2026Application for quotation of securities - IMU
9 July 2026Application for quotation of securities - IMU
7 July 2026Notification of cessation of securities - IMU
7 July 2026Change of Director's Interest Notice x5
7 July 2026Imugene Capital Raising Presentation
6 July 2026Proposed issue of securities - IMU
6 July 2026$P$11.1 Million Placement Completed to Advance azer-cel
6 July 2026Initial Director's Interest Notice - CG & MK
2 July 2026$PTrading Halt
1 July 2026$PNew Complete Response in the Concurrent BTKi azer-cel Cohort
30 June 2026$PFirst Complete Response in Concurrent BTKi azer-cel Cohort
9 June 2026$PAzer-cel Granted FDA Fast Track Designation for CLL and MZL
2 June 2026Notification regarding unquoted securities - IMU
31 May 2026azer-cel CAR-T naive data presented at ASCO Annual Meeting
27 May 2026$PFirst Patient in BTKi Combination Cohort of azer-cel study

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.